Pharmaceuticals

Zentalis is raising fresh capital via an underwritten public offering to fund trials and pre-commercial activities for its WEE1 inhibitor azenosertib in ovarian cancer.

Pulmovant will share Phase 2 results for inhaled sGC activator mosliciguat in PH-ILD at ERS Congress on 8 September 2026.

Topline results from the PHocus study will be presented at the European Respiratory Society Congress on 8 September, followed by an investor call.

S&P's upgrade to BBB- means Teva now holds investment-grade ratings from all three major agencies, capping a multi-month credit rehabilitation.

The NASDAQ-listed RNAi oncology biotech will use net proceeds to advance its Phase 2/3 SIL204 trial in locally advanced pancreatic cancer.

The Florida biotech has secured a USPTO notice of allowance covering HCW9302 as an alopecia areata treatment, as Phase 1 data show early signs of

IBA will co-lead end-of-life and waste-management work in a 91-partner EU initiative targeting PFAS removal from healthcare and pharmaceutical waste

NorthStrive Biosciences has formalised a six-month expansion programme to narrow four AI-discovered mitochondrial compounds toward a lead nomination in cardiac disease

A late-stage development advance in Centessa's OX2R agonist pipeline triggers an $8.6 million payment to Nxera, which retains future milestone and royalty

The USPTO notice covers LSD1 inhibitor combinations for myeloid cancers, with protection expected to run to 2042 pending formal grant.

Vivos Inc. has validated its PrecisionGel polymer platform in an Elsevier journal, supporting clinical programmes at Mayo Clinic and licensing talks with pharmaceutical

The NASDAQ-listed healthcare group reported 29.7% revenue growth in H1 2026 and repaid an $8m convertible note twelve months ahead of schedule.

The CRISPR biotech drew an initial $75m at closing, with further tranches tied to milestones for its HAE gene-editing candidate lonvo-z.

The Lp(a)HORIZON outcomes trial in 8,323 patients met its Lp(a)-lowering goal but did not reduce the composite cardiovascular endpoint versus

New modelling data links antibiotic disc exposure to clinical benefit, strengthening the rationale for PP353 as a targeted, non-opioid therapy for vertebrogenic lumbar

The HORIZON Phase 3 trial of pelacarsen failed its primary cardiovascular endpoint, but royalty backer Royalty Pharma says it still expects a modest positive return.

Palopegteriparatide gains a positive reimbursement recommendation in Canada for adults with chronic hypoparathyroidism inadequately controlled on standard therapy.

Phase 1 data show CLYM116 achieved near-complete APRIL suppression and a 29-day half-life, supporting quarterly dosing in IgA nephropathy.

Eledon Pharmaceuticals has submitted an IND for a registrational islet cell transplant study of tegoprubart, while reaffirming its Q4 2026 Phase 3 kidney trial start.

The Thousand Oaks biotech floated on Nasdaq in August 2026 and published NEJM data on its lead NaV 1.8 inhibitor onzotrigine in acute pain.